SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma

Autor: Zhou Zuwen, Yi Chen, Dong-Ze Lin, Yu-Ting Duan, Jiang Lihua, Liu Yanxin, Xingdong Zhao, Yu-xiang Wang, Yi Wang, Xi Zhang, Yiming Sun, Jian Ding, Meiyu Geng, Linghua Meng
Rok vydání: 2021
Předmět:
Zdroj: Acta Pharmacol Sin
ISSN: 1745-7254
1671-4083
DOI: 10.1038/s41401-021-00644-1
Popis: PI3Kδ is expressed predominately in leukocytes and overexpressed in B-cell-related malignances. PI3Kδ has been validated as a promising target for cancer therapy, and specific PI3Kδ inhibitors were approved for clinical practice. However, the substantial toxicity and relatively low efficacy as a monotherapy in diffuse large B-cell lymphoma (DLBCL) limit their clinical use. In this study, we described a novel PI3Kδ inhibitor SAF-248, which exhibited high selectivity for PI3Kδ (IC(50) = 30.6 nM) over other PI3K isoforms at both molecular and cellular levels, while sparing most of the other human protein kinases in the kinome profiling. SAF-248 exhibited superior antiproliferative activity against 27 human lymphoma and leukemia cell lines compared with the approved PI3Kδ inhibitor idelalisib. In particular, SAF-248 potently inhibited the proliferation of a panel of seven DLBCL cell lines (with GI(50) values
Databáze: OpenAIRE